Twenty-three @entity1 with @entity1582 were studied. They were grouped according to their clinical response and changes in @entity1582 globulin in the serum or urine while under chemotherapy. Sixteen responded favorably with clinical improvement and marked reduction in the respective M-globulins. Four did not respond and showed progression of disease, and three had short-lived clinical response with essentially unchanged @entity1582 -globulin values. @entity1 with @entity177 showed simultaneous improvement of @entity5507 and M-globulins in response to chemotherapy. Three @entity1 had solitary plasmacytomas when first seen, and dissemination occurred later in one. Combination of alkylating agents with @entity230 appeared to give faster, longer-lasting and more satisfactory clinical remissions, although the bone marrow may remain essentially unchanged. Radiation therapy was the most effective agent against @entity158 (without altering the M-globulin) when used alone. Twenty-two of the 23 @entity1 already had a significant decrease in IgM at the time @entity1582 was diagnosed. A diminution in IgM can be considered of diagnostic significance although the mechanism for this reduction is not known. It has been felt to involve a feed-back mechanism, where one immunoglobulin elevation results in a subsequent diminution in the other immunoglobulins.

XXXX . Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5507 :: ('MESH:D014511', 'Disease') :: ['uremia'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity158 :: ('MESH:D010146', 'Disease') :: ['localized pain'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']
@entity1582 :: (MESH:D009101,Disease) :: ['Multiple myeloma']
